NCT05370040View on ClinicalTrials.gov

THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

March 11, 2024

Study Completion Date

March 11, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

AAHI-SC2 Vaccine

AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine

BIOLOGICAL

AAHI-SC3 Vaccine

AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine

BIOLOGICAL

EUA or approved vaccine

Janssen or Pfizer vaccines (control arm)

Trial Locations (1)

Unknown

Wits Vida, Johannesburg

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY

NCT05370040 - THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines | Biotech Hunter | Biotech Hunter